Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75th annual meeting of the American Academy of Dermatology (AAD), which will take place March 3-7, 2017, in Orlando, Fla.
Lilly will present 14 abstracts, including one oral late-breaker presentation highlighting head-to-head data on the efficacy and safety of Taltz compared to Stelara®* (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis at 24 weeks.
"As the world's largest dermatology meeting, the American Academy of Dermatology annual meeting is an opportunity to highlight new information and data to experts in the dermatologic disease field," said Dr. Lotus Mallbris, global brand development leader, Taltz, Eli Lilly and Company. "Nearly one year after the approval of Taltz in the U.S. and Europe, we are proud to bring new data further demonstrating the efficacy and safety of Taltz to the American Academy of Dermatology annual meeting."
Studies, as well as the times and locations of the data sessions, are highlighted below.
Oral Late-Breaker Presentation
Saturday, March 4
- Abstract #5174: 9 a.m. - 11 a.m. ET
- Efficacy and Safety of Ixekizumab Compared to Ustekinumab after 24 Weeks of Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: Results from IXORA-S, a Randomized Head-to-Head Trial
- Presenter: Kristian Reich, M.D., Ph.D., Georg-August-University Göttingen and Dermatologikum Hamburg, Hamburg, Germany
- Location: F056 - Late-breaking Research: Clinical Trials
Poster Presentations
Sunday, March 5
- Abstract #4622: 8:15 a.m. - 8:20 a.m. ET
- The Effects of Age, Gender, Weight, Age at Onset, Psoriasis Severity, Nail Involvement and Presence of Psoriatic Arthritis at Baseline on the Efficacy of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
- Presenter: Orin Goldblum, M.D., Eli Lilly & Company, Indianapolis, IN
- Location: Psoriasis & Other Papulosquamous Disorders Section
- Abstract #4663: 8:20 a.m. - 8:25 a.m. ET
- Incidence of Inflammatory Bowel Disease Among Ixekizumab-treated Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Data from Eight Clinical Trials
- Presenter: Dana S. Hardin, M.D., St. Vincent Indianapolis Hospital & Heart Center, Indianapolis, IN
- Location: Psoriasis & Other Papulosquamous Disorders Section
- Abstract #4376: 9:15 a.m. - 9:20 a.m. ET
- Efficacy and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through 108 Weeks of a Randomized, Phase 3 Clinical Trial (UNCOVER-3)
- Presenter: Andrew Blauvelt, M.D., M.B.A., Oregon Medical Research Center, Portland, OR
- Location: Psoriasis & Other Papulosquamous Disorders Section
- Abstract #4551: 9:30 a.m. - 9:35 a.m. ET
- Clearing of Psoriasis within Different Body Regions Following 12 Weeks of Treatment with Ixekizumab
- Presenter: Andrew Blauvelt, M.D., M.B.A., Oregon Medical Research Center, Portland, OR
- Location: Psoriasis & Other Papulosquamous Disorders Section
- Abstract #4662: 11:25 a.m. - 11:30 a.m. ET
- Ixekizumab Treatment Shows a Neutral Impact on the Glucose and Lipid Profile of Patients with Moderate-to-Severe Psoriasis: Results from UNCOVER-1, -2, and -3
- Presenter: Jashin J. Wu, M.D., Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA
- Location: Psoriasis & Other Papulosquamous Disorders Section
- Abstract #4629: 12:50 p.m. - 12:55 p.m. ET
- Ixekizumab Efficacy in Patients with Moderate-to-Severe Plaque Psoriasis and Co-Morbid Psoriatic Arthritis: Four Year Results from a Phase 2 Study
- Presenter: Mark Lebwohl, M.D., Mount Sinai Hospital, New York City, NY
- Location: Psoriasis & Other Papulosquamous Disorders Section
- Abstract #4664: 2:20 p.m. - 2:25 p.m. ET
- Patient...
Read More
- Patient...
(All Rights Reserved)